Tolerability for older, persistence for younger: a real-world evidence on sacubitril/valsartan in an Asian heart failure cohort across age.

ABSTRACT:

Background

Sacubitril/Valsartan (S/V) benefits patients with heart failure with reduced ejection fraction (HFrEF), but its tolerability and clinical outcomes across age groups, especially the elderly, remain unclear. This real-world study evaluates these factors in an Asian cohort.

Methods

This retrospective cohort study analyzed data from the Treatment with Angiotensin Receptor Neprilysin Inhibitor for Taiwan Heart Failure Patients (TAROT-HF) registry (2017-2018). Patients were stratified into three age groups: <65, 65-74, and ≥75 years. Tolerability was defined as achieving at least 50% of the target S/V dosage (200 mg/day). Baseline characteristics, treatment doses, and clinical outcomes-including the composite of first unplanned heart failure hospitalization (HFH) or car

SUBMITTER: Chan PK 

PROVIDER: S-EPMC12321767 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature